查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1584095

糖肽抗生素市場，按給藥途徑、按藥物類型、按適應症、按最終用戶、按配銷通路、按國家和地區 - 2024-2032年產業分析、市場規模、市場佔有率和預測

Glycopeptide Antibiotics Market, By Route of Administration, By Drug Type, By Indication, By End User, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 322 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

報告要點

2023年糖肽抗生素市場規模為32.4073億美元，2024年至2032年年複合成長率為7.20%。

糖肽抗生素市場-市場動態

癌症和傳染病發生率上升推動市場需求

糖肽抗生素透過阻斷肽聚醣的產生來抑制細菌細胞壁的合成，這使其對於治療對BETA-內醯胺和其他抗生素具有抗藥性的多重抗藥性金黃色葡萄球菌（MRSA）和腸球菌感染非常重要。它們也是對 BETA-內醯胺過敏的患者的替代品。在癌症和傳染病發病率上升的推動下，糖肽抗生素市場預計在未來幾年將顯著成長。例如，美國疾病管制與預防中心（CDC）報告2019年新增資料病例 1,752,735 例，癌症相關死亡 599,589 例。前列腺癌、非何杰金氏淋巴瘤是最常見的惡性腫瘤。不斷增加的癌症負擔增加了對抗生素控制感染的需求，促進了市場成長。此外，腸球菌感染和結核病等傳染病的流行預計將進一步推動對糖肽抗生素的需求。根據 CDC2022年 9月的資料，美國2019年記錄了 8,916 例結核病病例。例如，2021年7月，AbbVie Inc.的DALVANCE獲得美國FDA批准，用於治療急性細菌性皮膚和皮膚結構感染（ABSSSI），為糖肽抗生素市場的預期成長做出了貢獻。

糖肽抗生素市場-關鍵見解

根據研究分析師分享的分析，預計全球市場在預測期內（2024-2032年）每年將以 7.20%左右的年複合成長率成長

根據藥物類型細分，Vancomycin預計將在2023年顯示最大市場佔有率

根據適應症細分，皮膚和結構感染是2023年的主導類型

依地區分類，北美是2023年的主要收入來源

糖肽抗生素市場-細分分析：

全球糖肽抗生素市場根據給藥途徑、藥物類型、適應症、最終用戶、配銷通路和地區進行細分。

市場依藥物類型分為四類：Vancomycin、Dalbavancin、Oritavancin、其他。在糖肽類抗生素市場，Vancomycin因其長期的臨床使用和對嚴重革蘭氏陽性菌感染，特別是抗二甲苯青黴素金黃色葡萄球菌（MRSA）的療效而被證明有效，仍然是主導藥物。它在醫院的廣泛使用，加上強大的安全性和廣泛的臨床證據，鞏固了其領導地位。儘管達Dalbavancin、Oritavancin等較新的替代品具有延長給藥間隔等優點，但它們尚未達到Vancomycin的市場佔有率。這主要是由於成本較高以及標準治療方案中對Vancomycin的既定偏好。

根據適應症，市場分為兩類：皮膚和結構性感染、腦膜炎、艱難梭菌感染、小腸結腸炎等。在適應症領域，皮膚和結構感染佔據最大的市場佔有率，這是由於其在醫療環境中的高發生率和抗生素抗藥性細菌發生率的上升所推動的。這些病例需要可靠的治療，因此糖肽抗生素非常重要。儘管其他病症（例如艱難梭菌感染和腦膜炎）也很重要，但皮膚和結構感染的流行和嚴重性質確保了它們在糖肽抗生素市場中的主導地位。

糖肽抗生素市場-地理洞察

北美是糖肽抗生素市場的主導地區，這主要是由於其先進的醫療基礎設施、抗生素抗藥性感染的高盛行率以及在研發方面的大量投資。該地區的醫院是這些抗生素（尤其是Vancomycin）的主要消費者，用於治療 MRSA 等嚴重的革蘭氏陽性感染。此外，支持性監管框架和對感染控制的高度重視導致對糖肽抗生素的需求不斷成長。該地區主要製藥公司的存在和進行中的臨床試驗進一步增強了其市場領導地位。

糖肽抗生素市場-競爭格局：

糖肽抗生素市場的公司採取各種策略來增強競爭力並確保產品可用性。這些努力的核心是研究和開發，重點是改進現有藥物配方並探索現有抗生素的新治療適應症。與醫療機構合作進行臨床試驗很常見，產生關鍵資料來支持這些治療的有效性和安全性。監管策略通常包括尋求快速通道指定，以加快新療法或改良療法的核准流程。此外，有針對性的行銷活動目的是教育醫療保健專業人員了解糖肽在管理抗藥性感染中的關鍵作用。此外，該公司還參與策略定價和償付談判，以確保更廣泛地獲得這些基本抗生素，促進其在臨床實踐中的永續使用。一些合作夥伴關係和產品發布促進了市場的成長。

最新進展：

2021年7月，AbbVie Inc.的DALVANCE獲得美國FDA批准，這是一種用於治療兒科患者急性細菌性皮膚和皮膚結構感染的抗生素。同樣，2020年7月，Sandoz International GmbH在美國市場推出了500毫克Daptomycin注射液，用於治療複雜的皮膚感染和某些血液感染。這些發展推動市場的擴張。

目錄

第1章 糖肽抗生素市場概述

  • 研究範圍
  • 市場預估年份

第2章 執行摘要

  • 市場摘錄
    • 依給藥途徑分類的糖肽抗生素市場摘錄
    • 依藥物類型分類的糖肽抗生素市場摘錄
    • 依適應症分類的糖肽抗生素市場摘錄
    • 依最終用戶分類的糖肽抗生素市場摘錄
    • 依配銷通路分類的糖肽抗生素市場摘錄
    • 依國家分類的糖肽抗生素市場摘錄
    • 依地區分類的糖肽抗生素市場摘錄
  • 競爭洞察

第3章 糖肽抗生素主要市場趨勢

  • 糖肽抗生素市場促進因素
    • 市場促進因素的影響分析
  • 糖肽類抗生素市場限制
    • 市場限制影響分析
  • 糖肽抗生素市場機會
  • 糖肽抗生素市場未來趨勢

第4章 糖肽抗生素產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第5章 糖肽抗生素市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的市場區隔
    • 邊際成長市場區隔
    • 最寬鬆的市場區隔
    • 邊際損失市場區隔

第6章 糖肽抗生素市場格局

  • 2023年糖肽抗生素市佔分析
  • 依主要製造商分類的細分資料
    • 既有參與者分析
    • 新興參與者分析

第7章 糖肽抗生素市場 - 依給藥途徑

  • 概述
    • 依給藥途徑分類的細分市場佔有率分析
    • 口服
    • 注射用
    • 其他

第8章 糖肽抗生素市場 - 依藥物類型

  • 概述
    • 依藥物類型分類的細分市場佔有率分析
    • Vancomycin
    • Dalbavancin
    • Oritavancin
    • 其他

第9章 糖肽抗生素市場 - 依適應症

  • 概述
    • 依適應症分類的細分市場佔有率分析
    • 皮膚和結構感染
    • 腦膜炎
    • 艱難梭菌感染
    • 小腸結腸炎
    • 其他

第10章 糖肽抗生素市場 - 依最終用戶

  • 概述
    • 依最終用戶分類的細分市場佔有率分析
    • 醫院
    • 專科診所
    • 居家護理
    • 其他

第11章 糖肽抗生素市場 - 依配銷通路

  • 概述
    • 依配銷通路分類的細分市場佔有率分析
    • 醫院藥房
    • 零售藥局
    • 網路藥局
    • 其他

第12章 糖肽抗生素市場 - 依地理位置

  • 介紹
    • 依地理位置分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美糖肽抗生素主要製造商
    • 北美市場規模和預測（依國家）
    • 北美市場規模與預測（依管理途徑）
    • 北美市場規模和預測（依藥物類型）
    • 北美市場規模和預測（依適應症）
    • 北美市場規模和預測（依最終用戶）
    • 北美市場規模和預測（依配銷通路）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲糖肽抗生素主要製造商
    • 歐洲市場規模和預測（依國家）
    • 歐洲市場規模與預測（依管理途徑）
    • 歐洲市場規模和預測（依藥物類型）
    • 歐洲市場規模與預測（依適應症）
    • 歐洲市場規模和預測（依最終用戶）
    • 歐洲市場規模和預測（依配銷通路）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區（APAC）
    • 概述
    • 亞太地區糖肽抗生素主要製造商
    • 亞太地區市場規模與預測（依國家）
    • 亞太地區市場規模與預測（依管理途徑）
    • 亞太地區市場規模和預測（依藥物類型）
    • 亞太地區市場規模與預測（依適應症）
    • 亞太地區市場規模和預測（依最終用戶）
    • 亞太地區市場規模和預測（依配銷通路）
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲糖肽抗生素主要製造商
    • 拉丁美洲市場規模與預測（依國家）
    • 拉丁美洲市場規模與預測（依管理途徑）
    • 拉丁美洲市場規模與預測（依藥物類型）
    • 拉丁美洲市場規模與預測（依適應症）
    • 拉丁美洲市場規模和預測（依最終用戶）
    • 拉丁美洲市場規模和預測（依配銷通路）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲糖肽抗生素主要製造商
    • 中東和非洲市場規模及預測（依國家）
    • 中東和非洲市場規模及預測（依管理途徑）
    • 中東和非洲市場規模及預測（依藥物類型）
    • 中東和非洲市場規模及預測（依適應症）
    • 中東和非洲市場規模及預測（依最終用戶）
    • 中東和非洲市場規模及預測（依配銷通路）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA其他地區

第13章 主要供應商分析-糖肽抗生素產業

  • 競爭儀表板
  • 公司簡介
    • F. Hoffmann-La Roche Ltd.
    • NATCO Pharma Limited
    • Teva Pharmaceutical Industries Ltd
    • LUPIN Limited
    • Amneal pharmaceuticals LLC
    • Zydus Cadila
    • Sun Pharmaceutical Industries Ltd.
    • Alembic Pharmaceuticals Limited
    • Mylan NV
    • Hetero Group
    • Others

第14章 360 度分析師視角

第15章 附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV4085

REPORT HIGHLIGHT

Glycopeptide Antibiotics Market size was valued at USD 3,240.73 Million in 2023, expanding at a CAGR of 7.20% from 2024 to 2032.

Glycopeptide antibiotics, such as vancomycin and teicoplanin, are primarily used to treat severe Gram-positive bacterial infections. They function by inhibiting bacterial cell wall synthesis, which is essential for bacterial growth and structural integrity. Vancomycin is often used to manage infections caused by resistant bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and Clostridioides difficile. These antibiotics are typically administered intravenously for systemic infections, while oral formulations are used to treat gastrointestinal infections. Due to their effectiveness against drug-resistant bacteria, glycopeptide antibiotics are crucial in hospital settings, particularly for managing complex infections and in surgical prophylaxis.

Glycopeptide Antibiotics Market- Market Dynamics

Increasing incidence of cancer and infectious diseases to propel market demand

Glycopeptide antibiotics inhibit bacterial cell wall synthesis by blocking peptidoglycan production, making them essential for treating multi-resistant Staphylococcus aureus (MRSA) and enterococcal infections that are resistant to beta-lactams and other antibiotics. They are also an alternative for patients allergic to beta-lactams. The market for glycopeptide antibiotics is expected to grow significantly in the coming years, driven by the rising incidence of cancer and infectious diseases. For example, the U.S. Centers for Disease Control and Prevention (CDC) reported 1,752,735 new cancer cases and 599,589 cancer-related deaths in 2019. Additionally, Globocan 2020 data showed 457,960 new cancer cases and 179,648 deaths in the U.K., with breast, prostate, and Non-Hodgkin's lymphoma being the most common malignancies. This rising cancer burden is increasing the demand for antibiotics to manage infections, boosting market growth. Moreover, the prevalence of infectious diseases, such as enterococcal infections and tuberculosis, is expected to further drive the demand for glycopeptide antibiotics. According to CDC data from September 2022, the U.S. recorded 8,916 tuberculosis cases in 2019. Additionally, new product approvals for treating infectious diseases are propelling market expansion. For instance, in July 2021, AbbVie Inc. received U.S. FDA approval for DALVANCE, used in the treatment of acute bacterial skin and skin structure infections (ABSSSI), contributing to the anticipated growth of the glycopeptide antibiotic market.

Glycopeptide Antibiotics Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.20% over the forecast period (2024-2032)

Based on Drug Type segmentation, Vancomycin was predicted to show maximum market share in the year 2023

Based on indication segmentation, skin and structure Infection was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Glycopeptide Antibiotics Market- Segmentation Analysis:

The Global Glycopeptide Antibiotics Market is segmented on the basis of Route of Administration, Drug Type, Indication, End User, Distribution Channel, and Region.

The market is divided into four categories based on Drug Type: Vancomycin, Dalbavancin, Oritavancin, Others. In the glycopeptide antibiotics market, Vancomycin remains the dominant drug due to its long-standing clinical use and proven efficacy against serious Gram-positive infections, particularly methicillin-resistant Staphylococcus aureus (MRSA). Its widespread use in hospitals, combined with a strong safety profile and extensive clinical evidence, reinforces its leadership. Although newer alternatives like Dalbavancin and Oritavancin offer benefits such as extended dosing intervals, they have not yet achieved Vancomycin's market share. This is primarily due to higher costs and the well-established preference for Vancomycin in standard treatment protocols.

The market is divided into two categories based on indication: Skin and Structure Infection, Meningitis, Clostridioides Difficile Infection, Enterocolitis and Others. In the indication segment, skin and structure infections hold the largest market share, driven by their high occurrence in healthcare environments and the rising incidence of antibiotic-resistant bacteria. The need for reliable treatments in these cases has made glycopeptide antibiotics essential. While other conditions, such as Clostridioides difficile infections and meningitis, are also important, the prevalence and critical nature of skin and structure infections ensure their dominant role in the glycopeptide antibiotics market.

Glycopeptide Antibiotics Market- Geographical Insights

North America is the dominating region in the glycopeptide antibiotics market, primarily due to its advanced healthcare infrastructure, high prevalence of antibiotic-resistant infections, and significant investments in research and development. The region's hospitals are major consumers of these antibiotics, particularly Vancomycin, to manage serious Gram-positive infections like MRSA. Furthermore, supportive regulatory frameworks and a strong emphasis on infection control contribute to the growing demand for glycopeptide antibiotics. The presence of key pharmaceutical companies and ongoing clinical trials in this region further enhance its market leadership.

Glycopeptide Antibiotics Market- Competitive Landscape:

Companies in the glycopeptide antibiotics market adopt various strategies to enhance competitiveness and ensure product availability. Central to these efforts is research and development, with a focus on improving existing drug formulations and exploring new therapeutic indications for current antibiotics. Collaborations with healthcare institutions for clinical trials are common, generating critical data to support the efficacy and safety of these treatments. Regulatory strategies often include pursuing fast-track designations to expedite the approval process for new or modified treatments. Furthermore, targeted marketing campaigns aim to educate healthcare professionals about the critical role of glycopeptides in managing drug-resistant infections. In addition, companies engage in strategic pricing and reimbursement negotiations to ensure broader access to these essential antibiotics, facilitating their sustainable use in clinical practice. Several partnerships and product launches have contributed to the market's growth.

Recent Developments:

In July 2021, AbbVie Inc. received U.S. FDA approval for DALVANCE, an antibiotic used to treat acute bacterial skin and skin structure infections in pediatric patients. Similarly, in July 2020, Sandoz International GmbH introduced a 500 mg Daptomycin injection in the U.S. market to treat complicated skin infections and certain bloodstream infections. These developments are boosting the market's expansion.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL GLYCOPEPTIDE ANTIBIOTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • F. Hoffmann-La Roche Ltd.
  • NATCO Pharma Limited
  • Teva Pharmaceutical Industries Ltd
  • LUPIN Limited
  • Amneal pharmaceuticals LLC
  • Zydus Cadila
  • Sun Pharmaceutical Industries Ltd.
  • Alembic Pharmaceuticals Limited
  • Mylan N.V.
  • Hetero Group
  • Others

GLOBAL GLYCOPEPTIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Parenteral
  • Others

GLOBAL GLYCOPEPTIDE ANTIBIOTICS MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

  • Vancomycin
  • Dalbavancin
  • Oritavancin
  • Others

GLOBAL GLYCOPEPTIDE ANTIBIOTICS MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Skin and Structure Infection
  • Meningitis
  • Clostridioides Difficile Infection
  • Enterocolitis
  • Others

GLOBAL GLYCOPEPTIDE ANTIBIOTICS MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

  • Hospital
  • Specialty Clinics
  • Homecare
  • Others

GLOBAL GLYCOPEPTIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies
  • Others

GLOBAL GLYCOPEPTIDE ANTIBIOTICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Glycopeptide Antibiotics Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Glycopeptide Antibiotics Market Snippet by Route of Administration
    • 2.1.2. Glycopeptide Antibiotics Market Snippet by Drug Type
    • 2.1.3. Glycopeptide Antibiotics Market Snippet by Indication
    • 2.1.4. Glycopeptide Antibiotics Market Snippet by End User
    • 2.1.5. Glycopeptide Antibiotics Market Snippet by Distribution Channel
    • 2.1.6. Glycopeptide Antibiotics Market Snippet by Country
    • 2.1.7. Glycopeptide Antibiotics Market Snippet by Region
  • 2.2. Competitive Insights

3. Glycopeptide Antibiotics Key Market Trends

  • 3.1. Glycopeptide Antibiotics Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Glycopeptide Antibiotics Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Glycopeptide Antibiotics Market Opportunities
  • 3.4. Glycopeptide Antibiotics Market Future Trends

4. Glycopeptide Antibiotics Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Glycopeptide Antibiotics Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Glycopeptide Antibiotics Market Landscape

  • 6.1. Glycopeptide Antibiotics Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Glycopeptide Antibiotics Market - By Route of Administration

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 7.1.2. Oral
    • 7.1.3. Parenteral
    • 7.1.4. Others

8. Glycopeptide Antibiotics Market - By Drug Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Drug Type, 2023 & 2032 (%)
    • 8.1.2. Vancomycin
    • 8.1.3. Dalbavancin
    • 8.1.4. Oritavancin
    • 8.1.5. Others

9. Glycopeptide Antibiotics Market - By Indication

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Indication, 2023 & 2032 (%)
    • 9.1.2. Skin and Structure Infection
    • 9.1.3. Meningitis
    • 9.1.4. Clostridioides Difficile Infection
    • 9.1.5. Enterocolitis
    • 9.1.6. Others

10. Glycopeptide Antibiotics Market - By End User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End User, 2023 & 2032 (%)
    • 10.1.2. Hospital
    • 10.1.3. Specialty Clinics
    • 10.1.4. Homecare
    • 10.1.5. Others

11. Glycopeptide Antibiotics Market - By Distribution Channel

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
    • 11.1.2. Hospital pharmacies
    • 11.1.3. Retail pharmacies
    • 11.1.4. Online pharmacies
    • 11.1.5. Others

12. Glycopeptide Antibiotics Market- By Geography

  • 12.1. Introduction
    • 12.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 12.2. North America
    • 12.2.1. Overview
    • 12.2.2. Glycopeptide Antibiotics Key Manufacturers in North America
    • 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.2.4. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.2.5. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.2.6. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 12.2.7. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.2.8. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.2.9. U.S.
      • 12.2.9.1. Overview
      • 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.9.3. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.2.9.4. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.2.9.5. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.2.9.6. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.2.9.7. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.2.10. Canada
      • 12.2.10.1. Overview
      • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.10.3. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.2.10.4. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.2.10.5. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.2.10.6. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.2.10.7. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.3. Europe
    • 12.3.1. Overview
    • 12.3.2. Glycopeptide Antibiotics Key Manufacturers in Europe
    • 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.3.4. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.3.5. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.3.6. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 12.3.7. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.8. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.9. Germany
      • 12.3.9.1. Overview
      • 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.9.3. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.9.4. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.9.5. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.9.6. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.9.7. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.10. Italy
      • 12.3.10.1. Overview
      • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.10.3. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.10.4. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.10.5. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.10.6. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.10.7. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.11. United Kingdom
      • 12.3.11.1. Overview
      • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.11.3. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.11.4. United Kingdom Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.11.5. United Kingdom Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.11.6. United Kingdom Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.11.7. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.12. France
      • 12.3.12.1. Overview
      • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.12.3. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.12.4. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.12.5. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.12.6. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.12.7. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.13. Russia
      • 12.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.13.2. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.13.3. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.13.4. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.13.5. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.13.6. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.14. Netherlands
      • 12.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.14.2. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.14.3. Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.14.4. Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.14.5. Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.14.6. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.15. Sweden
      • 12.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.15.2. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.15.3. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.15.4. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.15.5. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.15.6. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.16. Poland
      • 12.3.16.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.16.2. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.16.3. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.16.4. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.16.5. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.16.6. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.17. Rest of Europe
      • 12.3.17.1. Overview
      • 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.17.3. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.17.4. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.17.5. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.17.6. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.17.7. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.4. Asia Pacific (APAC)
    • 12.4.1. Overview
    • 12.4.2. Glycopeptide Antibiotics Key Manufacturers in Asia Pacific
    • 12.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.4.4. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.4.5. Asia Pacific Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.4.6. Asia Pacific Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 12.4.7. Asia Pacific Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.8. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.9. India
      • 12.4.9.1. Overview
      • 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.9.3. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.9.4. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.9.5. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.9.6. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.9.7. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.10. China
      • 12.4.10.1. Overview
      • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.10.3. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.10.4. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.10.5. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.10.6. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.10.7. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.11. Japan
      • 12.4.11.1. Overview
      • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.11.3. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.11.4. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.11.5. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.11.6. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.11.7. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.12. South Korea
      • 12.4.12.1. Overview
      • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.12.3. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.12.4. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.12.5. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.12.6. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.12.7. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.13. Australia
      • 12.4.13.1. Overview
      • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.13.3. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.13.4. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.13.5. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.13.6. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.13.7. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.14. Thailand
      • 12.4.14.1. Overview
      • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.14.3. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.14.4. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.14.5. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.14.6. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.14.7. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.15. Indonesia
      • 12.4.15.1. Overview
      • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.15.3. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.15.4. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.15.5. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.15.6. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.15.7. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.16. Philippines
      • 12.4.16.1. Overview
      • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.16.3. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.16.4. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.16.5. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.16.6. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.16.7. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.17. Rest of APAC
      • 12.4.17.1. Overview
      • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.17.3. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.17.4. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.17.5. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.17.6. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.17.7. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.5. Latin America
    • 12.5.1. Overview
    • 12.5.2. Glycopeptide Antibiotics Key Manufacturers in Latin America
    • 12.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.5.4. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.5.5. Latin America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.5.6. Latin America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 12.5.7. Latin America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.8. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.9. Brazil
      • 12.5.9.1. Overview
      • 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.9.3. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.9.4. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.9.5. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.5.9.6. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.5.9.7. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.10. Mexico
      • 12.5.10.1. Overview
      • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.10.3. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.10.4. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.10.5. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.5.10.6. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.5.10.7. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.11. Argentina
      • 12.5.11.1. Overview
      • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.11.3. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.11.4. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.11.5. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.5.11.6. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.5.11.7. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.12. Colombia
      • 12.5.12.1. Overview
      • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.12.3. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.12.4. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.12.5. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.5.12.6. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.5.12.7. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.13. Rest of LATAM
      • 12.5.13.1. Overview
      • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.13.3. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.13.4. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.13.5. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.5.13.6. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.5.13.7. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.6. Middle East and Africa
    • 12.6.1. Overview
    • 12.6.2. Glycopeptide Antibiotics Key Manufacturers in Middle East and Africa
    • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.6.4. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.6.5. Middle East and Africa Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.6.6. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 12.6.7. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.8. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.9. Saudi Arabia
      • 12.6.9.1. Overview
      • 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.9.3. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.9.4. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.9.5. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.6.9.6. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.6.9.7. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.10. United Arab Emirates
      • 12.6.10.1. Overview
      • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.10.3. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.10.4. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.10.5. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.6.10.6. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.6.10.7. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.11. Israel
      • 12.6.11.1. Overview
      • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.11.3. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.11.4. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.11.5. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.6.11.6. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.6.11.7. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.12. Turkey
      • 12.6.12.1. Overview
      • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.12.3. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.12.4. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.12.5. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.6.12.6. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.6.12.7. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.13. Algeria
      • 12.6.13.1. Overview
      • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.13.3. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.13.4. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.13.5. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.6.13.6. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.6.13.7. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.14. Egypt
      • 12.6.14.1. Overview
      • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.14.3. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.14.4. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.14.5. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.6.14.6. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.6.14.7. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.15. Rest of MEA
      • 12.6.15.1. Overview
      • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.15.3. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.15.4. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.15.5. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.6.15.6. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.6.15.7. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Glycopeptide Antibiotics Industry

  • 13.1. Competitive Dashboard
  • 13.2. Company Profiles
    • 13.2.1. F. Hoffmann-La Roche Ltd.
    • 13.2.2. NATCO Pharma Limited
    • 13.2.3. Teva Pharmaceutical Industries Ltd
    • 13.2.4. LUPIN Limited
    • 13.2.5. Amneal pharmaceuticals LLC
    • 13.2.6. Zydus Cadila
    • 13.2.7. Sun Pharmaceutical Industries Ltd.
    • 13.2.8. Alembic Pharmaceuticals Limited
    • 13.2.9. Mylan N.V.
    • 13.2.10. Hetero Group
    • 13.2.11. Others

14. 360 Degree Analyst View

15. Appendix

  • 15.1. Research Methodology
  • 15.2. References
  • 15.3. Abbreviations
  • 15.4. Disclaimer
  • 15.5. Contact Us